Core Insights - Veeva Systems has expanded its Veeva Vault QMS to enhance management of medtech field actions and product recalls, improving oversight, timeliness, and accuracy throughout the process [1][2][3] Group 1: New Capabilities - The new features in Veeva Vault QMS will facilitate the entire field action process, including issue identification, evaluation, planning, execution, and monitoring through to closure [1] - The integration of field actions and recall management with adjacent quality processes such as complaint handling and quality risk management reduces manual transcription needs, thereby enhancing efficiency [2] Group 2: Industry Collaboration - Veeva has collaborated closely with industry partners like Teleflex to develop these capabilities, aiming to streamline processes and improve customer service [2] - The company emphasizes the importance of understanding industry needs to deliver solutions that enhance agility in critical processes related to product quality and patient safety [3] Group 3: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [4] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [4]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

Veeva Systems (VEEV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VEEV broke through the 20-day moving average, which suggests a short-term bullish trend. The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages. Sim ...

Company Performance - Veeva Systems' shares have increased by 20.5% over the past three months, outperforming both the industry and the S&P 500 Index, driven by strong quarterly results, product expansion, and new partnerships [1] - The company reported a 15% increase in revenue year-over-year for the second quarter, with a 19% rise in recurring subscriptions, exceeding market expectations [2] - Veeva achieved a 32% improvement in operating profit and generated nearly $850 million in free cash flow during the first two quarters of fiscal 2025 [4] Revenue and Earnings Guidance - Veeva raised its revenue guidance for fiscal 2025 to between $2,704 million and $2,710 million, slightly above previous estimates [5] - Subscription revenues for fiscal 2025 are now expected to be $2,257 million, an increase from the prior outlook of $2,245 million [6] - Adjusted EPS for fiscal 2025 is projected to be $6.22, up from the previous guidance of $6.16 [7] New Partnerships and Product Developments - Veeva introduced new capabilities to its Veeva Site Connect, enhancing sponsor-site collaboration for clinical trials, which is expected to reduce trial time and costs [8] - The company partnered with Vita Global Sciences to enhance clinical data management, aiming for faster trials and improved patient outcomes [9] - Hangzhou Tigermed Consulting also signed a deal with Veeva to modernize electronic data capture and streamline data management processes [10] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, at a CAGR of 11.3%, driven by an increase in clinical trials and integration with healthcare technologies [11]

The cloud software leader charged higher after a strong quarterly earnings report. Shares of Veeva Systems (VEEV 3.10%) rose 12.8% in August, according to data provided by S&P Global Market Intelligence. The company reported excellent quarterly financial results, and the stock's attractive valuation translated to gains as investors revised their forecasts higher. Veeva had a stellar quarterly report Veeva reported quarterly earnings on Aug. 28, sending the stock higher. The company achieved 15% revenue grow ...

Veeva Systems Inc. (VEEV) recently announced the newest release of Veeva Site Connect. The release adds powerful new capabilities and a streamlined site-centric experience to simplify and standardize sponsor-site collaboration, thus taking a major step forward for clinical trial execution. Per management, sponsors would be able to reduce the time and effort of site start-up, study conduct and closeout for higher-quality trials at a significantly lower cost with Veeva Site Connect. Following the release anno ...

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more knowledgeable and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, assisting investors in selecting stocks likely to outperform the market in the next 30 days [2] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Group 3: Value, Growth, and Momentum Scores - Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - Growth Score evaluates a company's financial health and future outlook based on earnings, sales, and cash flow [4] - Momentum Score assesses stocks based on price trends and earnings estimate changes to identify favorable buying opportunities [4] Group 4: VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [5] Group 5: Zacks Rank and Performance - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [6] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7] Group 6: Stock Example - Veeva Systems (VEEV) - Veeva Systems Inc. specializes in cloud-based software applications for the life sciences sector, with products including Veeva CRM and Veeva Vault [10] - VEEV currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B and a Momentum Style Score of B, having increased 19% in the past four weeks [11] - The Zacks Consensus Estimate for VEEV's fiscal 2025 earnings has risen by $0.06 to $6.21 per share, supported by upward revisions from eight analysts [11][12]

Did you analyze how Veeva Systems (VEEV) fared in its international operations for the quarter ending July 2024? Given the widespread global presence of this provider of cloud-based software services for the life sciences industry, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for it ...

The company is in the middle of a big transition. As a leading software company catering to the healthcare sector, Veeva Systems (VEEV 0.51%) has provided solid growth while operating in a defensive industry. The stock has had a good year, up over 10%, but it has trailed the market over the past five years even as management takes the business in a new direction. Let's dive into the company's most recent results and see if now is the time to buy the stock. Strong revenue growth For its fiscal second quarter ...

New capabilities and simple, standard site experience cut trial time and expense Fixed price implementation to get up and running quickly Industry advances to connected trials as seven of the top 20 biopharmas adopt Veeva Site Connect PLEASANTON, Calif., Sept. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced, in a major step forward for clinical trial execution, the newest release of Veeva Site Connect, adding powerful new capabilities and a streamlined site-centric experience to simplify ...